Loading...

Astellas Pharma Inc.

ALPMY•PNK
Healthcare
Drug Manufacturers - General
$15.10
$-0.33(-2.14%)
U.S. Market opens in NaNh NaNm

Astellas Pharma Inc. (ALPMY) Stock Overview

Explore Astellas Pharma Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap27B
P/E Ratio13.21
EPS (TTM)$0.44
ROE0.20%
Fundamental Analysis

AI Price Forecasts

1 Month$15.15
3 Months$20.93
1 Year Target$14.50

ALPMY Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Astellas Pharma Inc. (ALPMY) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 36.74, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $14.50.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 13.21 and a market capitalization of 27B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-1.81%
5-Day Change
-7.06%
1-Month Change
-5.84%
3-Month Change
5.43%
6-Month Change
42.25%
Year-to-Date (YTD) Change
14.00%
1-Year Change
50.60%
3-Year Change
2.23%
5-Year Change
2.92%
All-Time (Max) Change
97.27%

Contact Information

https://www.astellas.com
81 3 3244 3000
2-5-1, Nihonbashi-Honcho, Tokyo, NaN, 103-8411

Company Facts

14,754 Employees
IPO DateDec 29, 2009
CountryJP
Actively Trading

Frequently Asked Questions